scholarly journals MP7: FAMILIES WITH BOTH NON-HODGKIN'S LYMPHOMA (NHL) AND MYELOMA (MM): ANTICIPATION AND MALE TRANSMISSION

2016 ◽  
Vol 64 (3) ◽  
pp. 807.1-807
Author(s):  
PH Wiernik ◽  
JP Dutcher

Purpose of StudyTo determine whether genetic rather than environmental factors may be responsible for the occurrence of these neoplasms in families.Methods UsedWe interrogated our registry of >700 pedigrees of families (fams) with multiple hematologic malignancies. We identified 31 fams with both NHL and MM in their pedigrees. In 16 pedigrees a parent and child were affected (12 father-child pairs and 4 mother-child pairs). Fifteen affected sib pairs were identified in the 31 fams, 10 same sex pairs and 5 male-female pairs. Six of the 31 pedigrees had only 1 affected pair. More distant relationships were observed in other fams.Summary of ResultsMale transmission was evident in 25 fams and female transmission was observed in 6. NHL and MM cases had at least 1 unaffected generation (gen) between them in 8 pedigrees, and the diseases occurrred in sequential (13 fams) or the same gen in 10 fams. MM was the diagnosis (dx) in the youngest affected gen in 9 pedigrees, NHL in 13 pedigrees and both occurred in the youngest gen in 9 fams. The median age at dx of 29 NHL patients for whom data were available was 55 yrs (range, 20–99 yrs), and the median age at dx of 26 MM cases was 56 yrs (range, 30–82 yrs). Ten of 26 MM patients were <50 years old at dx. The presence or absence of anticipation could be assessed in 15 of the 31 pedigrees. All 15 displayed anticipation in terms of succeeding gens developing NHL or MM at an earlier age than did the previous gens (median −19 yrs, range −6 to −56 yrs).ConclusionsWe demonstrate anticipation in 15 assessible fams with both NHL and MM, a feature of familial MM that we previoiusly reported (Despande HA, et al: Br J Haematol 1998). More advanced, aggressive disease at dx in the youngest gen is another feature of anticipation, and was observed in 9 of 13 fams in which it could be assessed. Demonstration of anticipation in all 15 evaluable fams suggests a genetic basis for the relationship between these two B-cell disorders. The increase of same sex sib pairs among affected sib pairs implicates a locus on a pseudo-autosomal region of the X chromonsome as potentially responsible for this observation, as we have previously reported for Hodgkin's lymphoma (Horwitz M, Wiernik PH, Am J Hum Genet 1999). Myeloma and non-Hodgkin's lymphoma may have common genetic causation; molecular studies of these fams are planned.

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 1388-1388
Author(s):  
Mireille Guerin ◽  
Cynthia Therien ◽  
Gorazd Krosl ◽  
Jinzi J. Wu ◽  
Helene Dulude ◽  
...  

Abstract Prostate secretory protein 94 (PSP-94) has been shown to exert anti-tumor activity against prostate cancer cells, particularly in the form of PCK3145, a synthetic peptide corresponding to amino acids 31–45 of PSP-94. Indeed, when tested in a murine model, this peptide could reduce experimental prostate tumour growth. In addition, when evaluated in a Phase I clinical study, this peptide demonstrated a particularly interesting safety profile, with almost complete lack of toxicity. In order to determine whether PCK3145 could exert cytotoxic activity against other marrow infiltrating cancers, we tested its activity both in vitro and in vivo against non-Hodgkin’s lymphoma (NHL) and other hematologic cancers. Interestingly, PCK3145 inhibited the proliferation of human NHL (SR) and myeloma (RPMI-8226) cell lines in vitro. To explore its anti-tumor activity in vivo, the impact of PCK3145 was also measured by inoculating P815 malignant cells into syngeneic DBA mice. First, four groups of 6 DBA mice were injected subcutaneously with 2x104 P815 cells and then treated with subcutaneous injections of PCK3145, and compared to a peptide with the scrambled amino acid sequence, PCK5266 (peptide derived from amino acids 52 to 66 of PSP-94), and phosphate-buffered saline (PBS). Treatment with PCK3145 significantly decreased the growth of P815 tumours in comparison to PBS (p<0.001), scrambled peptide (p<0.05) and PCK5266 (p<0.01), confirming in vivo anti-tumor activity and suggesting that tumour growth inhibition is due to the specific amino acid sequence of PCK3145. The same model was used to determine the effect of PCK3145 on metastatic dissemination following intraperitoneal administration of the peptide. PCK3145 treatment led to a decreased number of liver metastasis compared to PBS (p<0.05) and scrambled peptide (p<0.05) controls. In order to determine whether PCK3145 exerted its activity by altering metalloproteinase release, metalloproteinase MMP-9 levels were measured 3 weeks post-tumor cell exposure. MMP-9 levels, measured by ELISA, in the peripheral blood of treated P815 bearing mice were similar to those obtained with healthy animals (12.83±1.890 (mean±SD) ng/ml and 7.183±0.4070 ng/ml, respectively), while MMP-9 levels were elevated in mice treated with PBS and scrambled peptide (35.12±8.559 ng/ml and 22.60±3.944 ng/ml, respectively; p<0.05). We next tested PCK3145 treatment on human SR lymphoma cell line grown subcutaneously in NOD/SCID mice. Similarly to results obtained with murine tumors, treatment with PKC3145 resulted in significant inhibition of SR non-Hodgkin’s lymphoma growth compared to treatment with PBS (p<0.001) and scrambled peptide (p<0.01). These results demonstrate that in vivo treatment with PCK3145 can reduce tumor cell proliferation of both murine and human hematologic cancers. In addition, PCK3145 has the potential to inhibit tumor cells dissemination by lowering MMP-9 secretion. Thus, PCK3145 represents a unique peptide demonstrating sequence-specific anti-tumor activity against NHL and other hematologic malignancies. Based on these results, clinical studies are being designed to evaluate its therapeutic activity in humans.


2021 ◽  
Vol 5 (4) ◽  
pp. 134-138
Author(s):  
Glazydia Juwita Rachma ◽  
Ugroseno Yudho Bintoro ◽  
Mia Ratwita Andarsini ◽  
Novira Widajanti

Non-Hodgkin's lymphoma is a major public health problem with over 14.1 million people are diagnosed with it (2012). In the same year there were 8.2 million deaths due to cancer. The purpose of this study was to determine the relationship between clinical manifestations and the degree of malignancy based on histopathological features in patients with Non-Hodgkin's Lymphoma. This study used a retrospective analytical method with a cross-sectional approach using the patient's medical record at RSUD Dr. Soetomo, Surabaya who was diagnosed with Non-Hodgkin Lymphoma from 1st January 2015 to 31st December 2017. In this study, there were 139 samples include those criteria, with a greater number of male samples (62.6%) compared to women (37.4%). This study showed that 49.3% of patients with non- Hodgkin's lymphoma in RSUD Dr. Soetomo with clinical manifestations without symptoms actually experience malignancy with a high degree, this showed that clinical manifestations without symptoms are not always associated with a low level of malignancy. Then, based on the Chi Square test results obtained p-value of 0.289 (>0.05), so there was no significant relationship between clinical manifestations and the degree of malignancy. Keywords: lymphoma; manifestation; histopatological


2017 ◽  
Vol 2017 ◽  
pp. 1-4 ◽  
Author(s):  
Luciana Munhoz ◽  
Felipe Pereira Marcos Marsan ◽  
Emiko Saito Arita

Non-Hodgkin’s lymphoma (NHL) is a lymphoproliferative disorder, from a subgroup of heterogeneous hematologic malignancies; the term “extranodal” refers to malignant involvement of tissues other than lymph nodes, tonsils, spleen, pharyngeal lymphatic ring, or thymus. Only 0.6% of all NHL are at mandible alone, and it may involve the inferior alveolar canal. We describe a case of bilateral enlargement of the mandibular canal without symptomatology, which was shown in a panoramic radiograph and cone beam computed tomography in a rehabilitation routine exam, as an early sign of primary extranodal NHL.


1989 ◽  
Vol 158 (1) ◽  
pp. 3-7 ◽  
Author(s):  
Riaz M. Jan-Mohamed ◽  
Susan J. Armstrong ◽  
John Crocker ◽  
Michael J. Leyland ◽  
Maj A. Hulten

2020 ◽  
Vol 3 (3) ◽  
pp. 211-216
Author(s):  
T.S. Kotomina ◽  
◽  
E.A. Baryakh ◽  
E.N. Misyurina ◽  
E.I. Zhelnova ◽  
...  

Recent years have seen the increase in the rate of childbirth after the age of 30 years. This is associated with higher risks for a mother and a child as well as higher rate of cancers diagnosed during pregnancy including non-Hodgkin’s lymphoma (NHL). The data on pregnancy-associated NHLs are limited by individual case studies. This makes difficult to develop a therapeutic strategy for lymphoma and pregnancy management in women with hematologic malignancies. The paper addresses the case study of a rare combination of Burkitt’s lymphoma and pregnancy. At 20 weeks of the pregnancy, right ovarian tumor was identified by magnetic resonance imaging. Burkitt’s lymphoma was verified by the biopsy of the excised ovary. Progressive tumor growth required chemotherapy. R-DA-EPOCH chemotherapy program was successful and also allowed for pregnancy prolongation and led to favorable perinatal outcome.KEYWORDS: pregnancy, Burkitt’s lymphoma, non-Hodgkin’s lymphoma, chemotherapy, remission, adnexectomy.FOR CITATION: Kotomina T.S., Baryakh E.A., Misyurina E.N. et al. Burkitt’s lymphoma and pregnancy. Advantages of today’s medicine. Russian Journal of Woman and Child Health. 2020;3(3):211–216. DOI: 10.32364/2618-8430-2020-3-3-211-216


Sign in / Sign up

Export Citation Format

Share Document